ContraFect Corporation Stock

Equities

CFRXQ

US2123264093

Biotechnology & Medical Research

Market Closed - OTC Markets 01:37:23 2024-07-12 pm EDT 5-day change 1st Jan Change
0.0155 USD -12.68% Intraday chart for ContraFect Corporation +2.65% -48.33%
Sales 2021 - Sales 2022 - Capitalization 4.19M
Net income 2021 -20M Net income 2022 -65M EV / Sales 2021 -
Net cash position 2021 51.02M Net cash position 2022 10.8M EV / Sales 2022 -
P/E ratio 2021
-4.77 x
P/E ratio 2022
-0.06 x
Employees 23
Yield 2021 *
-
Yield 2022
-
Free-Float 99.98%
More Fundamentals * Assessed data
Dynamic Chart
1 day-12.68%
1 week+2.65%
Current month-25.84%
1 month+3.33%
3 months-13.41%
6 months-61.15%
Current year-48.33%
More quotes
1 week
0.02
Extreme 0.0152
0.03
1 month
0.01
Extreme 0.0131
0.03
Current year
0.01
Extreme 0.0111
0.04
1 year
0.01
Extreme 0.0111
1.37
3 years
0.01
Extreme 0.0111
363.20
5 years
0.01
Extreme 0.0111
1 071.92
10 years
0.01
Extreme 0.0111
4 992.00
More quotes
Date Price Change Volume
24-07-12 0.0155 -12.68% 3,261
24-07-11 0.0178 +10.25% 55,638
24-07-10 0.0161 -20.30% 454
24-07-09 0.0202 -11.40% 13,217
24-07-08 0.0228 +50.99% 2,151

Delayed Quote OTC Markets, July 12, 2024 at 01:37 pm EDT

More quotes
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
More about the company